Gilead gives up on $15M MASH bet after mulling preclinical data
Oct 11, 2024 · The U.S. drugmaker has “mutually agreed” to terminate its collaboration and license agreement with South Korean biotech Yuhan for a pair of MASH therapies.
Yuhan eyes next Leclaza with R&D, open innovation after U.S.
Aug 23, 2024 · Following the U.S. approval of lung treatment Leclaza, Korea’s first cancer drug to achieve the milestone, Yuhan Corporation is now seeking the next breakthrough with a renewed focus on research and development (R&D).
Yuhan Corporation to invest 1.6 billion Won (1.34 million USD) in Yuhan …
Nov 8, 2021 · Yuhan Corporation is spurring overseas open innovation expansion and strengthening its global position by continuously investing in ‘Yuhan USA’, a leading edge for global advancement.
J&J’s Janssen Inks Deal With Korea’s Yuhan for NSCLC ... - BioSpace
Nov 6, 2018 · South Korea-based Yuhan Corporation inked a licensing deal with Janssen for a non-small cell lung cancer drug candidate called lazertinib that has the potential to be worth up to $1.25 billion, the company announced late Monday.
Yuhan inks $80.9M deal with Gilead Sciences for HIV drug …
Sep 20, 2024 · Yuhan has secured an $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drugmaker announced in an electronic disclosure on Friday.
Yuhan - Wikipedia
Yuhan Corporation (Korean: 주식회사 유한양행; Hanja: 株式會社 柳韓洋行; RR: Jusik Hoesa Yuhan Yanghaeng) is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962.
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
May 31, 2023 · Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda, wagering up to $325 million to get its hands on a preclinical HER2 tyrosine kinase inhibitor...
[INTERVIEW] Yuhan USA is searching for its next promising …
Jan 11, 2023 · Yuhan, a Seoul-based biopharmaceutical company best known for its licensing of a novel lung cancer treatment called lazertinib, sold under brand Leclaza, has clinched a deal with Yansen to export the drug and is now looking for its next target.
News – Yuhan USA
Aug 20, 2024 · News – Yuhan USA. RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.
[Herald Interview] Yuhan aims for bigger presence in US
Jan 11, 2023 · SAN FRANCISCO – South Korean pharmaceutical giant Yuhan is seeking to increase cooperation with researchers and biotechnology firms based in the US, with hopes to benefit from the nation’s...